The pharma split-up movement is spreading. Baxter International says it will spin off its biopharma business into a separate company, leaving its $9 billion medical products business to venture on under the Baxter name.
written on 27.03.2014
The pharma split-up movement is spreading. Baxter International says it will spin off its biopharma business into a separate company, leaving its $9 billion medical products business to venture on under the Baxter name.
See our Cookie Privacy Policy Here